抗器官纤维化药物研究进展  

Advances in the research of anti-organ fibrosis drugs

作　　者：任强 张陆勇 李政 REN Qiang;ZHANG Lu-yong;LI Zheng(School of Pharmacy,Guangdong Pharmaceutical University,Guangzhou 510006,China)

机构地区：[1]广东药科大学药学院,广东广州510006

出　　处：《药学学报》2020年第11期2510-2528,共19页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金资助项目(81803341);广东省重点领域研发计划(2019B020201002);广东省自然科学基金资助项目(2018A030313445,2019A1515011036);广东药科大学“创新强校工程”项目(2018KTSCX111);广东省中医药局科研项目(20191199)。

摘　　要：纤维化是一种以组织瘢痕为特征的病理过程,可发生于人体的多种器官。器官纤维化表现为器官组织内纤维结缔组织增多和实质细胞减少,可致器官结构破坏和功能减退,严重危害人类健康。当前治疗器官纤维化的策略主要有:阻断转化生长因子-β1(transforming growth factor-β1,TGF-β1)/Smad蛋白(Smad proteins,Smad)信号通路、抗炎、调节鞘氨醇激酶-1/鞘氨醇-1-磷酸(sphingosine kinase 1/sphingosine-1-phosphate,SK1/S1P)信号通路、拮抗血管活性肽受体、酶抑制剂、激酶抑制剂、细胞信号通路抑制剂、调节代谢途径和间充质干细胞治疗。本文分别综述了器官纤维化的治疗策略和抗器官纤维化药物的研究进展,为抗器官纤维化药物的研发提供参考。Fibrosis is a pathological process characterized by tissue scars and can occur in many organs of the human body.Organ fibrosis is manifested by increased fibrous connective tissue and reduced parenchymal cells in organ tissues,which can lead to destruction of organ structures and reduced function,which seriously endangers human health.Current strategies for treating organ fibrosis include:blocking the transforming growth factor-β1(TGF-β1)/Smad signaling pathway,anti-inflammatory,regulating the sphingosine kinase 1/sphingosine-1-phosphate(SK1/S1 P)signaling pathway,antagonizing vasoactive peptide receptors,enzyme inhibitors,kinase inhibitors,inhibitors of cellular signaling pathway,regulation of metabolic pathways,and mesenchymal stem cell therapy.In the review,the treatment strategies for organ fibrosis and the latest developments in the research of anti-organ fibrosis drugs are summarized to provide a reference for the development of anti-organ fibrosis drugs.

关 键 词：纤维化 器官纤维化 治疗策略 抗纤维化药物 细胞信号转导 作用机制 

分 类 号：R914.4[医药卫生—药物化学]